港股詳情

本页面由TTMF Limited提供服务

英派藥業-B待上市

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：2.34億

香港流通股本：2.34億

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

市銷率: - -

1

开始申购

05/05

2

申購截止

05/08 10:15

3

公布中签

05/11

4

暗盘

05/12 16:15 - 18:30

5

挂牌上市

05/13

總覽公司新聞資訊公告

新股孖展統計 | 5月6日

智通财经网

「港股合成致死腫瘤藥第一股」英派藥業啓動招股，明星基石加持，擬5月13日上市

即將亮相：港股合成致死腫瘤藥第一股英派藥業

医药投资部落

港股18A再迎明星biotech，英派藥業招股開始，合成致死稀缺標的獲豪華基石認購

信阳新闻网

BRIEF-劑泰科技和英派藥業香港IPO開始招股，分別募資約21億港元及9億港元

《新股》英派藥業(07630.HK)今招股集資最多9.1億入場費4,394元

阿斯达克财经

中國英派藥業計劃通過香港IPO籌資至多1.17億美元--發行條款清單

IMPACT Therapeutics（南京英派藥業）擬全球發售：最高發售價21.75港元，合共發行約4,197,900股香港公開發售股份

禮來3億美金收購臨床前階段下一代雙載荷ADC平台，英派藥業同賽道佈局

合成致死2.0：PARP之後，誰是下一個百億靶點？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/07630/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派藥業-B","latestPrice":0,"timestamp":1778054400000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":234000000,"shares":234000000,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"05-06 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":8,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":0,"ipoDetail":{"name":"英派药业－Ｂ","exchange":"SEHK","listingDate":"2026-05-13","sharesOutstanding":276165130,"sharesFloat":276165130,"offerAmount":41977000,"priceRange":"19.750 - 21.750","market":"HK","openProspectusDate":"2026-05-05","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0505/2026050500024_c.pdf","purchaseBeginDate":"2026-05-05","purchaseEndDate":"2026-05-08","winningDate":"2026-05-12","currency":"HKD","minPurchaseQuantity":200,"peRate":-17.52,"use":"1、约51%或398.37百万港元将用于为核心产品塞纳帕利正在进行及计划中的临床开发、监管批准以及商业化提供资金；\n2、约31%或242.15百万港元将用于为关键产品IMP1734及IMP9064正在进行的临床开发提供资金；\n3、约8%或62.49百万港元将用于为其他管线资产、IMP1707、IMP7068、IMP22、IMP25、IMP08、IMP13及IMP10的研发活动提供资金；\n4、约8%或62.49百万港元将用于为研发平台的开发及扩大药物管线提供资金；\n5、约2%或15.62百万港元将用于营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家处于商业化阶段的创新驱动型生物技术公司，致力于在全球范围内推进基于合成致死(synthetic lethality)机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌一线维持疗法，适用于全人群（无论突变状态），并展现出令人信服的临床特征。通过整合小分子药物与新兴疗法（包括新型抗体偶联药物和蛋白降解剂）的自主研发平台，公司持续推动创新突破。","subscribed":86.91,"marketCap":5454000000,"minimumCapital":4393.88,"overAllotment":true,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,1250000,1500000,1750000,2098800","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-05-12","greyDateTimestamp":1778515200000,"greyOpeningTime":1778573700000,"greyClosingTime":1778581800000,"showGreyQuote":false,"openProspectusDate":"2026-05-05","listingDate":"2026-05-13"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":234000000,"roa":"--","roe":"--","lyrEps":0,"shares":234000000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/07630\",,undefined,":{"id":9966,"type":"COMMON","ipoName":"07630-IPO","symbol":"07630","companyName":"英派藥業-B","market":"HK","currency":"HKD","status":"OPEN","underwriter":"高盛(亞洲)有限責任公司","lotSize":200,"minQty":200,"expectedOfferingSize":41977000,"openingDate":1777944600000,"closingDate":1778206500000,"commonClosingDate":1778206500000,"allotmentDate":1778428800000,"listDate":1778601600000,"marginable":true,"marginRate":10,"latestPrice":21.75,"minPrice":19.75,"maxPrice":21.75,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0505/2026050500024_c.pdf","allowedQuantities":[200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,1250000,1500000,1750000,2098800],"interestRate":0,"recommend":false,"isHint":false,"interestStartDate":1778169600000,"interestEndDate":1778342400000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1778573700000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[{"ipoName":"07630-IPO","ipoId":9966,"financingId":59526,"type":1,"availableFundLimit":4393.86,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":43938.6,"maxSubscribeLimit":-1,"marginRate":10,"interestRate":0,"openTime":1777944600000,"closeTime":1778206500000,"isAtValidTime":true,"subscriptionMethod":"FINANCING","processFee":0,"supportPI":false,"applyFundLimit":4393.86,"threshold":50000000000,"isAvailable":false},{"ipoName":"07630-IPO","ipoId":9966,"financingId":59519,"type":4,"availableFundLimit":4393.86,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":0,"maxSubscribeLimit":-1,"marginRate":100,"interestRate":0,"openTime":1777944600000,"closeTime":1778206500000,"isAtValidTime":true,"subscriptionMethod":"CASH","processFee":0,"supportPI":false,"applyFundLimit":4393.86,"threshold":50000000000,"isAvailable":false}],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[{"method":"FINANCING","closeTime":1778206500000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":4393.86},{"method":"CASH","closeTime":1778206500000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":4393.86}],"latestClosingDate":1778206500000,"subscribedFinanceRatio":86.91,"subscribedRatio":86.91,"forecastRatio":118.2,"raiseMoney":91300000,"totalMargin":7935490000,"quoteInfoUpdatedAt":1778098049770,"prospectusUpdatedAt":1778048316000,"forecastMarketValue":5730426447.5,"minForecastMarketValue":5454261317.5,"maxForecastMarketValue":6006591577.5,"sharesOutstanding":276165130,"business":"公司是一家處於商業化階段的創新驅動型生物技術公司，致力於在全球範圍內推進基於合成致死(synthetic lethality)機制的精準抗癌療法，打造創新療法，以滿足癌症患者未被滿足的醫療需求。公司自主研發的核心產品塞納帕利已在中國獲批上市，作為卵巢癌一線維持療法，適用於全人群（無論突變狀態），並展現出令人信服的臨床特徵。通過整合小分子藥物與新興療法（包括新型抗體偶聯藥物和蛋白降解劑）的自主研發平台，公司持續推動創新突破。","greyOpeningTime":1778573700000,"greyClosingTime":1778581800000,"tradable":true,"showClawback":true,"clawbackType":"機制B","clawbackRate":10},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633918418","title":"新股孖展統計 | 5月6日","url":"https://stock-news.laohu8.com/highlight/detail?id=2633918418","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633918418?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 18:27","pubTimestamp":1778063248,"startTime":"0","endTime":"0","summary":"英派药业-B(07630)、剂泰科技-P(07666)正在招股中。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260506/20260506182748_22433.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260506/20260506182748_22433.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["07666","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114924651","title":"「港股合成致死腫瘤藥第一股」英派藥業啓動招股，明星基石加持，擬5月13日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1114924651","media":"同壁财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114924651?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 15:27","pubTimestamp":1778052443,"startTime":"0","endTime":"0","summary":"据消息，南京英派药业股份有限公司于2026年5月5日至8日开启招股， 公司拟全球发售约4198万股H股，每股发售价最高至21.75港元，募资规模最高超9亿港元。公司预计将于2026年5月13日在港股主板上市。其中，IMP32是全球首个、且目前唯一靶向CEACAM5的TOP1i+ATRi双载荷ADC，凭借明确的合成致死协同效应，已成为全球巨头战略布局的核心方向。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tongbicapital.com/news?id=1116351&feClassCode=hsag","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1668077363049","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123297572","title":"即將亮相：港股合成致死腫瘤藥第一股英派藥業","url":"https://stock-news.laohu8.com/highlight/detail?id=1123297572","media":"医药投资部落","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123297572?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 15:25","pubTimestamp":1778052358,"startTime":"0","endTime":"0","summary":"汇聚了中国创新药行业核心资产的港股18A板块，即将迎来又一家创新药细分赛道的龙头企业：有着“合成致死肿瘤药第一股”之称的英派药业，已在5月5日开启港股招股流程，预计5月13日于香港联交所主板挂牌上市。新技术赛道扩展市场往往习惯将英派药业定位为一家深度绑定合成致死赛道的小分子药物公司，这一判断并不全面。这意味着，英派药业的技术半径正从合成致死小分子药物赛道，延伸到围绕肿瘤治疗的多种前沿技术路线。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/IRYuOSKv3y13KkTaFyQC4A?from=groupmessage&scene=1&subscene=10000&sessionid=1778048506&clicktime=1778050535&enterid=1778050535&ascene=1&fasttmpl_type=0&fasttmpl_fullversion=8237539-zh_CN-zip&fasttmpl_flag=0&realreporttime=1778050535337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1629166856219","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633092917","title":"港股18A再迎明星biotech，英派藥業招股開始，合成致死稀缺標的獲豪華基石認購","url":"https://stock-news.laohu8.com/highlight/detail?id=2633092917","media":"信阳新闻网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633092917?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 19:43","pubTimestamp":1777981409,"startTime":"0","endTime":"0","summary":"2026年5月5日，南京英派药业股份有限公司（简称“英派药业”，股票代码:07630.HK）开启招股，拟全球发售约4198万股H股(视乎发售量调整权及超额配股权行使与否而定)，其中中国香港发售股份约420万股，国际发售股份约3778万股；2026年5月5日至5月8日招股，每股发售价格最高至21.75港元，每手买卖单位为200股，募集资金规模最高超9亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.p5w.net/roll/finance/202605/t20260505_6469559.htm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1778052843920","symbols":["07630","BK4087","BK4588","VXUS","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633998585","title":"BRIEF-劑泰科技和英派藥業香港IPO開始招股，分別募資約21億港元及9億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633998585","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633998585?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 09:29","pubTimestamp":1777944565,"startTime":"0","endTime":"0","summary":"BRIEF-剂泰科技和英派药业香港IPO开始招股，分别募资约21亿港元及9亿港元据香港联交所公告显示：中国人工智能驱动医药纳米材料解决方案提供商--剂泰科技7666.HK全球发售2.01229亿股H股，发售价每股10.5港元，联席保荐人为富瑞、德意志银行以及中信证券，预计H股于5月13日开始在香港联交所买卖中国生物技术公司英派药业7630.HK全球发售4,197.7万股H股，最高发售价每股21.75港元，联席保荐人为高盛以及中金公司，预计H股于5月13日开始在香港联交所买卖","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL6S41I012:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07666","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633998874","title":"《新股》英派藥業(07630.HK)今招股集資最多9.1億 入場費4,394元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633998874","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633998874?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 08:58","pubTimestamp":1777942680,"startTime":"0","endTime":"0","summary":"处于商业化阶段的生物技术公司英派药业-B 今日起至本周五招股，计划发行4197.7万股H股，一成于香港作公开发售，每股招股价介乎19.75元至21.75元，集资最多9.1亿元，每手200股，一手入场费4393.9元。英派药业收入来源于对外许可收入及销售医药产品，去年录得收入3,825.1万元人民币(下同)，按年升14%，研发开支1.8亿元，减少5.7%，年内净亏损近3亿元，增16%。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142909241_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142909241_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1522570/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1522570/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633960607","title":"中國英派藥業計劃通過香港IPO籌資至多1.17億美元--發行條款清單","url":"https://stock-news.laohu8.com/highlight/detail?id=2633960607","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633960607?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 08:41","pubTimestamp":1777941705,"startTime":"0","endTime":"0","summary":"中国英派药业计划通过香港IPO筹资至多1.17亿美元--发行条款清单路透新加坡5月5日 - 据路透周二看到的一份发行条款清单，中国抗癌药物开发商英派药业7630.HK计划通过在香港首次公开发行筹资至多1.17亿美元。英派药业计划以每股19.75至21.75港元的价格发行4198万股股份。若承销商行使超额配售权，此次募资规模可能增至1.34亿美元。包括腾讯0700.HK在内的六家基石投资者将认购约3570万美元的股份。英派药业预计将于5月11日确定IPO价格，并于5月13日上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL6S41I00E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999000327.SGD","SG9999014914.USD","SG9999001069.SGD","LU0543330483.HKD","LU0823413660.USD","SG9999018857.SGD","LU0516423174.USD","SG9999007991.SGD","LU0080751232.USD","LU2251237306.USD","LU0329678170.USD","LU0210533765.USD","SG9999014898.SGD","LU1251922891.USD","LU0320764243.SGD","LU0359201612.USD","SG9999017495.SGD","LU0823413587.USD","LU0370786039.SGD","SG9999015952.SGD","LU0828237940.HKD","SG9999015945.SGD","LU1188198961.HKD","BK1521","LU0650527681.SGD","LU1917777945.USD","LU0708995583.HKD","LU0791591158.USD","LU0348788117.USD","SG9999001093.SGD","LU0314109678.HKD","LU2097828805.USD","LU2237443465.HKD","SG9999015986.USD","LU0456842615.SGD","LU1226287792.SGD","LU0499858602.USD","IE00BF5LJ272.USD","LU1568876251.USD","LU1366334651.USD","SG9999006514.SGD","LU0588546209.SGD","LU0211331839.USD","LU0235996351.USD","IE00B031HY20.USD","LU0516422366.SGD","LU0049112450.USD","LU1813983027.USD","LU0449509016.USD","LU0823426480.USD","LU1880383440.USD","LU0164872284.USD","LU0979878070.USD","LU2449936058.SGD","LU0210526637.USD","LU0865486749.SGD","LU0320764599.SGD","LU1316542783.SGD","LU0106959298.USD","LU1868838027.USD","LU0261950983.USD","LU0244354667.USD","LU0871576103.HKD","LU1044876610.USD","LU1235295612.USD","LU1048596156.SGD","IE0008369823.USD","LU0048580855.USD","LU1718418525.SGD","LU0821914370.USD","LU2023250504.SGD","BK1591","LU0577902298.EUR","LU0819123356.HKD","LU0128522744.USD","LU1282648689.USD","LU1691799644.USD","HK0000306701.USD","LU1733274390.USD","LU0106259558.USD","LU0327786744.USD","LU2476274720.SGD","IE00B031J352.USD","LU0828238088.HKD","HK0000352382.USD","LU1196710195.USD","IE00B3M56506.USD","LU0127658192.USD","BK1609","LU0540923850.HKD","LU0516422440.USD","HK0000914686.HKD","LU1051769294.HKD","LU0441854154.USD","LU0737861772.HKD","LU1226288253.USD","LU0501845795.SGD","IE00B0JY6N72.USD","LU1719994722.HKD","LU1481107354.HKD","LU0320764755.SGD","LU0143863784.USD","LU2294711473.HKD","LU0345769128.USD","BK1531","LU0675040207.SGD","HK0000352291.HKD","LU1044874839.SGD","BK1526","LU2008162690.USD","LU0039217434.USD","LU0029874905.USD","LU0608807433.USD","LU0231483743.USD","LU2462611646.USD","LU0828237510.HKD","LU1733274473.HKD","LU0577902611.USD","BK1516","LU0651946864.USD","LU0084288322.USD","LU0117841782.USD","IE00BQXX3D17.EUR","LU0072462343.USD","LU0269904917.USD","LU0210527791.USD","LU2476274308.USD","LU0169518387.USD","LU0856984785.SGD","LU0561508036.HKD","LU0873338254.USD","LU0329678337.USD","LU0878005551.USD","LU2087589342.USD","LU2265009873.SGD","LU0737861699.HKD","LU0132412106.USD","LU1323998911.USD","LU0049853897.USD","LU0823397103.USD","LU0918141887.USD","IE00BQXX3C00.GBP","LU0188438112.USD","LU1868837722.USD","LU1102505929.USD","LU1008478684.HKD","SG9999013353.USD","LU0228367735.SGD","LU0315179316.USD","LU1504937902.USD","LU0784639295.USD","LU2317271919.USD","LU2039709279.SGD","SG9999003461.SGD","LU0880133367.SGD","LU0165289439.USD","LU1303224171.USD","LU0348805143.USD","LU0488056044.USD","LU0878004406.USD","LU1152091168.USD","LU1974910355.USD","LU1102505762.USD","LU1282649067.USD","BK1502","LU1152091754.HKD","LU0414403682.SGD","LU0890818403.SGD","LU0700851271.USD","LU0456827905.SGD","LU0516423091.SGD","IE0032834883.USD","LU0106252389.USD","LU2125910500.SGD","LU1568876335.HKD","LU0886674414.USD","LU1961090484.USD","LU0196878994.USD","LU0708995153.HKD","LU1226287875.USD","IE00B29SXG58.USD","LU2362541273.HKD","LU2498475776.HKD","LU1366334578.USD","LU1804176565.USD","LU0882747503.HKD","LU1196710864.SGD","LU2237443895.HKD","LU0175139822.USD","IE0003895053.USD","BK1608","IE00B8L5B284.USD","LU0181495838.USD","LU0463099449.HKD","IE00B0169L03.USD","LU0011963245.USD","LU0572944931.SGD","LU0456846285.SGD","LU0862451837.USD","LU1807302812.USD","LU2051468812.USD","LU0449515922.USD","LU0823040885.USD","LU2125910849.SGD","LU0348827113.USD","BK1589","LU0328353924.USD","LU0228659784.USD","IE00B0169N27.USD","LU0572939691.SGD","LU1242518857.USD","LU0149721374.USD","LU0067412154.USD","LU0140636845.USD","LU0307460666.USD","LU0359201885.HKD","LU0117844026.USD","LU1105468828.SGD","LU0287142896.SGD","IE0001KFT4U8.USD","LU2152927971.USD","LU0052750758.USD","SG9999014674.SGD","LU0918141705.HKD","LU0054237671.USD","LU2045819591.USD","LU0164880469.USD","LU0577902371.SGD","LU2237443382.USD","LU0326950275.SGD","LU1868837565.USD","LU2247934214.USD","LU0396098781.USD","LU0862451753.SGD","LU0642271901.SGD","LU2362540622.SGD","LU0823038988.USD","LU1960683339.HKD","SG9999014906.USD","LU0588545730.USD","SG9999015978.USD","LU0348825331.USD","LU0211977185.USD","LU1770036033.HKD","LU1048588211.SGD","BK1095","LU1734074674.USD","HK0000320264.USD","BK1615","LU0651947912.USD","LU0543330566.HKD","LU1048484197.HKD","LU0502904849.HKD","IE0032431581.USD","LU0348783662.USD","LU1226287529.USD","LU0797268264.HKD","HK0000151867.HKD","LU2293587155.HKD","LU0634319403.HKD","LU0607220059.USD","LU2257852520.SGD","SG9999004220.SGD","LU1211504680.USD","IE00BQXX3F31.USD","LU0823041008.USD","LU1769817179.HKD","LU0786609619.USD","LU1282651121.HKD","LU1064131003.USD","LU0633140560.USD","LU1226288170.HKD","LU1242518931.SGD","LU0173614495.USD","LU0043850808.USD","LU2778985437.USD","LU1282651048.USD","LU1226288097.SGD","LU0572940350.SGD","SGXZ31699556.SGD","LU1224709979.USD","LU0047713382.USD","LU2097828557.USD","LU2226246903.HKD","LU0051755006.USD","LU0541501648.USD","LU2097828714.EUR","LU2279701549.SGD","SGXZ81514606.USD","IE00B8HQ1Z84.USD","LU0541502299.USD","IE00BZ08YT58.USD","LU0823039010.USD","LU0164865239.USD","LU2177674079.SGD","HK0001040168.HKD","LU2237443622.USD","LU0516422952.EUR","LU0348783233.USD","LU0359202008.SGD","LU0149534421.HKD","LU0384037296.USD","LU0192582467.USD","LU1328277881.USD","LU2097828631.EUR","LU1642822792.SGD","LU0061477393.USD","SG9999006597.SGD","LU2106854487.HKD","LU0605514214.HKD","SG9999018865.SGD","LU2097828474.EUR","LU0254981946.USD","LU0823426308.USD","LU2133065610.SGD","LU1720050803.USD","LU1688375341.USD","07630","LU0203347892.USD","LU1282649810.SGD","LU0577902538.SGD","LU0831103253.SGD","TCHmain","LU1814569148.SGD","LU0029875118.USD","IE00B067MR52.USD","LU1808992512.USD","HK0001040143.USD","IE0034224299.USD","LU0633140727.USD","LU0345776255.USD","SGXZ90724238.SGD","LU1439102457.SGD","LU1051768304.USD","LU1880383366.USD","IE0009570106.USD","LU2251237488.HKD","LU1675838814.USD","HK0000306685.HKD","IE00BZ08YS42.EUR","SG9999014880.SGD","LU0163747925.USD","IE00B031HW06.USD","HK0000914660.USD","SG9999002463.SGD","LU0348735423.USD","LU0348723411.USD","LU0611395673.USD","BK1586","LU0264606111.USD","IE0008368742.USD","LU1064130708.USD","LU1725190679.HKD","LU0469268626.HKD","LU1770034418.SGD","LU0259732245.USD","LU0417516902.SGD","LU0738912210.USD","LU0348784397.USD","LU0972618739.USD","LU0348816934.USD","LU0048388663.USD","LU0293314216.USD","LU1993786604.SGD","SG9999002562.SGD","IE00B97KM107.HKD","IE00BGV7N243.SGD","SG9999002828.SGD","LU0648948544.HKD","HK0000320223.HKD","LU0593848301.USD","IE0031814852.USD","LU0348814723.USD","LU0509642566.USD","SG9999001903.USD","LU0577902454.USD","LU1831875114.USD","LU0107464264.USD","LU1515016050.SGD","LU0823397285.USD","LU1046422090.SGD","LU0128522157.USD","LU2242644610.SGD","LU0326948709.USD","BK1517","HTCD.SI","LU0417516738.SGD","LU0203345920.USD","LU2148510915.USD","LU0589944569.HKD","LU1328615791.USD","LU1629966141.USD","IE0003795394.USD","LU0214875030.USD","LU1769817096.USD","LU1951186391.HKD","LU0143863198.USD","LU0048597586.USD","SG9999001226.SGD","LU1785774172.SGD","LU0345769631.USD","LU0868486357.SGD","LU0251144936.SGD","LU0531970944.HKD","LU1282649141.HKD","LU0672654166.SGD","SGXZ99366536.SGD","IE0003851619.USD","LU1023057109.AUD","LU0261947096.USD","LU0985320562.USD","SG9999001689.USD","LU1794554557.SGD","LU0791590937.USD","LU0819121731.USD","LU0417516571.SGD","SG9999000418.SGD","LU0898667661.SGD","LU0499858438.USD","LU0345775950.USD","LU0070217475.USD","SG9999000459.SGD","LU1810669033.SGD","LU2362541513.USD","SG9999001846.SGD","SG9999001051.SGD","LU0289960550.SGD","LU0315178854.USD","LU1224444064.USD","IE0008368411.USD","LU0608807946.USD","LU0096374516.USD","LU1044875133.USD","LU2237443978.SGD","LU1883866441.USD","BK1610","LU3063872942.SGD","IE00BZ08YR35.GBP","LU0594300419.USD","LU2399975544.HKD","LU0531971595.HKD","LU1439103000.SGD","LU1956131251.USD","GB00BDT5M118.USD","IE00B5MMRT66.SGD","LU0683595622.HKD","LU2237443549.SGD","IE00BPRC5H50.USD","LU0229945570.USD","LU1655091459.SGD","LU1196710351.USD","LU1981816686.USD","LU0588545490.SGD","LU0072913022.USD","LU0594300179.USD","LU0588545904.SGD","BK1618","LU0431992006.USD","LU0054450605.USD","LU0455707207.USD","SGXZ51526630.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122813661","title":"IMPACT Therapeutics（南京英派藥業）擬全球發售：最高發售價21.75港元，合共發行約4,197,900股香港公開發售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1122813661","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122813661?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 06:27","pubTimestamp":1777933676,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc成立于2009年，专注于基于“合成致死”机制的肿瘤精准治疗药物研发，核心在研产品涵盖PARP1/2抑制剂、ATR抑制剂等，用于多种肿瘤适应症的临床试验。公司在全球布局多条研发管线，核心产品包括IMP4297、IMP1734、IMP9064等，覆盖卵巢癌、乳腺癌、前列腺癌、小细胞肺癌等领域。本次全球发售初步拟发行合共41,977,000股H股，其中4,197,900股用于香港公开发售，余下37,779,200股用于国际发售，另设最高6,296,400股的超额配股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"IMPACT Therapeutics（南京英派药业）拟全球发售：最高发售价21.75港元，合共发行约4,197,900股香港公开发售股份","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1154131856","title":"禮來3億美金收購臨床前階段下一代雙載荷ADC平台，英派藥業同賽道佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=1154131856","media":"药融圈","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154131856?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 18:53","pubTimestamp":1777546436,"startTime":"0","endTime":"0","summary":"成为全球巨头战略布局的核心方向。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/VTcssL2b253Xs-2m2RQC0w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1613031030984","symbols":["07630","LLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160945600","title":"合成致死2.0：PARP之後，誰是下一個百億靶點？","url":"https://stock-news.laohu8.com/highlight/detail?id=1160945600","media":"研发客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160945600?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 18:35","pubTimestamp":1777545344,"startTime":"0","endTime":"0","summary":"后来者如何突围？","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/54M7yaODrjrTV0UB9cnrLQ?scene=1&click_id=1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1777545367960","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}